<DOC>
	<DOCNO>NCT02398279</DOCNO>
	<brief_summary>This study evaluate addition L-Arginine usual regimen treatment schizophrenia adult . As requisite crossover design , half participant start L-Arginine half placebo switch three week use one week washout period .</brief_summary>
	<brief_title>L-arginine add-on Therapy Patients With Schizophrenia</brief_title>
	<detailed_description>L-arginine precursor nitric oxide ( NO ) , neuromodulator dopamine , gamma-aminobutyrate ( GABA ) glutamate system . Nitric oxide donor increase NO level cellular level could improve N-methyl-D-aspartate ( NMDA ) receptor dysfunction . Using L-arginine could bypass block NMDA receptor improve therapeutic efficacy reverse dysfunction . The investigator propose use L-Arginine , dietary supplement culture , might constitute safe option add-on treatment may display beneficial effect positive , negative , cognitive affective symptom associate schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>SchizophreniaSchizoaffective Disorder Clinical Global Impression &gt; 4 Able take oral medication likely comply required evaluation On stable medication regimen 8 week Competent willing give inform consent Uncontrolled medical illness ( renal disease , hepatic , cardiac disease , gout , asthma , diabetes , sickle cell anemia , lowhigh blood pressure ) History Myocardial Infarction ( MI ) History genital herpes infections/ receive lysine contain treatment Pregnancy/ lactation Substance relate Addictive Disorders Drugs might induce hypotension Intolerance Larginine ingredient placebo Larginine capsule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>L-Arginine</keyword>
	<keyword>nitric oxide</keyword>
	<keyword>drug augmentation</keyword>
</DOC>